Compare Globus Medical Inc. Class A Common Stock (GMED) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Visa Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Visa Inc trades at $395.33 (market cap $743.55B). The key difference: Visa Inc is far larger — about 72.5× Globus Medical Inc. Class A Common Stock's market cap, and Visa Inc pays a 0.68% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Visa Inc for 115 Days on average.
| GMED | V | |
|---|---|---|
Market Cap | $10.25B | $743.55B |
Volume | 1,108,124 | 7,478,804 |
Sector | Health | Financials |
52-Week High | $96.82 | $396.06 |
52-Week Low | $58.33 | $295.52 |
Typical Hold Time | 0 Days | 115 Days |
Enterprise Value | $9.76B | $754.13B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Visa (V) trades at $396.06, up 1.74% today, near its 52-week high. The stock shows strong technical momentum with bullish moving averages and key resistance at $399. Fundamentally, Visa reported robust earnings beats in recent quarters, with Q2 2026 results due April 28. Revenue grew to $40B in 2025, with a net income margin of 50.78%, though the P/E ratio of 33.71 is elevated. Recent news highlights Visa's push into AI-driven commerce and stablecoin partnerships.
Outlook remains positive with 85% analyst buy ratings and a $423.29 consensus target, implying 7% upside. Risks include competitive fintech threats and regulatory scrutiny. Strong cash flow and institutional accumulation support long-term growth, but high valuation requires sustained execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
